Role and Clinical efficacy of Subconjunctival Injection Bevacizumab in Nonsurgical Management of Pterygium

Abstract

Introduction: Pterygium progression and recurrence is a common complication. In various studies conducted on role of subconjunctival depot injection of bevacizumab, nothing has been standardized with regards to dosage and its frequency. The study was done with aim to assess role and clinical efficacy of subconjunctival injection of bevacizumab as a non surgical treatment modality for pterygium. Material and Methods: 80 cases of pterygium were included in this study. Study was done over a period of 12 months from December 2018 to November 2019 at a tertiary care ophthalmic centre of Northern India. In this study, three doses of 2.5 mg of bevacizumab were administered sub-conjunctivally at monthly interval under topical anaesthesia on Outdoor Patient Department basis. Standard aseptic measures were observed. Results: Cases were followed up next day after each injection and thereafter on monthly basis for three months and finally after 06 months of first injection. Progression of pterygium was noted in 8 cases. Subconjunctival haemorrhage was noted in 41 cases. Conjunctival cyst was seen in three cases which were punctured in OPD, however recurrence was noted after one month in one case. No rise in Intra Ocular Pressure (IOP) was noted. Conclusions: Subconjunctival injection of bevacizumab is useful in treatment of patients with pterygium without local or systemic adverse effects.